Myelodysplastic Syndrome: Our Clinical Trials

Your Memorial Sloan-Kettering physician can help you decide whether treatment through a clinical trial is right for you. Sometime clinical trials should be considered as the first treatment for myelodysplastic syndromes (MDS). If you have already received standard treatments, then clinical trials may be an option to consider in addition to supportive care.

Here you can find a continually updated listing of Memorial Sloan-Kettering's current clinical trials for adults with MDS. To learn more about a study, choose from the list below.

Showing 19 trials
Title Investigator
A Phase I Study of Actinium-225-Labeled HuM195 Antibody in Patients with Advanced Myeloid Malignancies
[Protocol 02-017] 		Douer, Dan, MD
A Phase I Study of EPZ-5676 in Patients with Relapsed/Refractory Leukemia and Other Advanced Hematologic Cancers
[Protocol 12-181] 		Tallman, Martin, MD
A Phase I Study of Plerixafor as a Chemosensitizing Agent for Children with Relapsed Acute Leukemia or Myelodysplastic Syndromes
[Protocol 11-208] 		Trippett, Tanya, MD
A Phase I Study of WT1-Sensitized T cells for Residual or Relapsed Leukemia after Allogeneic Hematopoietic Progenitor Cell Transplantation
[Protocol 07-055] 		O'Reilly, Richard, MD
A Phase I/II Trial of Clofarabine, Melphalan, and Thiotepa Followed by an Allogeneic Stem Cell Transplant for the Treatment of High-Risk and/or Advanced Hematologic Malignancies
[Protocol 06-125] 		Boulad, Farid, MD
A Phase II Study of Bulk Versus Fractionated Stem Cell Infusions in Patients with Hematologic Cancers Undergoing Stem Cell Transplantation
[Protocol 12-016] 		Giralt, Sergio, MD
A Phase II Study of Palifermin with or without Leuprolide After T-Cell-Depleted Allogeneic Stem Cell Transplantation
[Protocol 12-077] 		Goldberg, Jenna, MD
A Phase II Study of Peri-transplant Palifermin followed by an Allogeneic T-Cell-Depleted Stem Cell Transplant in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved from MDS
[Protocol 08-008] 		Castro-Malaspina, Hugo, MD
A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia
[Protocol 08-031] 		Boulad, Farid, MD
A Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant
[Protocol 07-035] 		Hsu, Katharine, MD, PhD
A Phase II Trial of Transplants from HLA-Compatible Donors with T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System for the Treatment of Patients with Hematologic Malignancies and Disorders
[Protocol 10-050] 		O'Reilly, Richard, MD
A Phase III Study of Lenalidomide Alone and in Combination with Epoetin Alfa in Patients with Myelodysplastic Syndromes and Symptomatic Anemia
[Protocol 10-128] 		Klimek, Virginia, MD
A Phase III Study of Pomalidomide versus Placebo in Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis Who Are Dependent on Red Blood Cell Transfusions
[Protocol 11-025] 		Rampal, Raajit, MD
A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Acute Leukemia or Myelodysplasia
[Protocol 08-087] 		Barker, Juliet, MBBS
A Study of Allogeneic Stem Cell Transplantation in HIV-Infected Patients with Hematologic Cancers
[Protocol 12-092] 		Sauter, Craig, MD
A Study of Posaconazole Versus Micafungin to Protect Against Invasive Fungal Infections in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome
[Protocol 10-038] 		Papanicolaou, Genovefa, MD
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLA-Compatible Donor
[Protocol 12-053] 		O'Reilly, Richard, MD
Cyclophosphamide, Fludarabine, and Total Body Irradiation Followed by the Transplantation of Unrelated Double-Unit Donor Umbilical Cord Blood Grafts for Patients with Hematological Malignancy
[Protocol 06-014] 		Barker, Juliet, MBBS
Transplantation of Unrelated Donor Double-Unit Cord Blood with T-Cell-Depleted Stem Cells for Patients with High-Risk Hematologic Cancers
[Protocol 12-153] 		Barker, Juliet, MBBS
Related Topics
Recommended Links

Making an Appointment

Contact our Physician Referral Service to schedule a consultation with a Memorial Sloan-Kettering physician in Manhattan or at one of our suburban regional cancer centers.

Learn more »

Other Useful Information